Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion type Assertion NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_head.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion description "[The HER2-lytic hybrid peptide was effective even in breast cancer cell lines that are resistant to trastuzumab and/or lapatinib in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_provenance.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion evidence source_evidence_literature NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_provenance.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion SIO_000772 23358664 NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_provenance.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion wasDerivedFrom befree-2016 NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_provenance.
- NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_assertion wasGeneratedBy ECO_0000203 NP1047966.RAFS5rpf_G1f1Jm8JVlQMWPVyISuAyEXRB53ye_hIeRzc130_provenance.